ClinicalTrials.Veeva

Menu

Pharmacokinetics Study of Donepezil HCl in Subjects Receiving Haemodialysis.

Eisai logo

Eisai

Status and phase

Completed
Phase 4

Conditions

End-Stage Renal Disease

Treatments

Drug: donepezil HCl

Study type

Interventional

Funder types

Industry

Identifiers

NCT01063556
E2020-J081-107

Details and patient eligibility

About

The purpose of this study is to investigate the pharmacokinetics of donepezil HCl 3 mg in subjects with end-state renal disease who were receiving haemodialysis.

Full description

This is a randomised, single-center, open-label, single-dose, two-period crossover pharmacokinetics study of donepezil HCl tablets 3 mg in subjects receiving haemodialysis. Subjects will be or will not be receiving haemodialysis. After intervals of over 15 days, the subjects will be receiving the other treatment.

Enrollment

6 patients

Sex

All

Ages

20 to 79 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subjects with end-stage renal disease who were receiving haemodialysis. Subject who are able and willing to give written informed consent.

Exclusion criteria

Subjects with known hypersensitivity to drugs or foods. Subjects with a corrected QT interval greater than 450 msec at Screening period.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

6 participants in 2 patient groups

1
Experimental group
Treatment:
Drug: donepezil HCl
Drug: donepezil HCl
2
Experimental group
Treatment:
Drug: donepezil HCl
Drug: donepezil HCl

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems